Levolta Pharmaceuticals Presents Phase II Study Results for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Levolta Pharmaceuticals Presents Phase II Study Results for Potential Osteoarthritis Therapy at ACR Annual Meeting

BETHLEHEM, Pa., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Levolta Pharmaceuticals, Inc. today presented the results of an exploratory Phase II study for a potential disease modifying drug for patients with knee osteoarthritis (OA) at the 2014 American College of Rheumatology (ACR) Annual Meeting in Boston, demonstrating that its investigational VOLT01 had "superior efficacy and safety" when compared to zoledronic acid (ZA), which was used as a positive control.

In a single blind, single center study, 32 subjects with knee osteoarthritis were randomized to receive either intravenous VOLT01 or ZA in a 1:1 ratio. At 48 hours post treatment, patients were assessed for common ZA side effects, including fatigue, body aches, joint pains, fever and myalgia, symptoms. Follow-up evaluations at six months examined knee pain by visual analogue scale and bone marrow density. The clinical trial results showed that VOLT01 significantly reduced pain (35mm vs. 10mm) as compared to ZA when measured by the change in mean Visual Analogue Scale (VAS) and significantly decreased the incidence of Post-Dose Syndrome (PDS) (12.5% vs. 56.3%) as compared to ZA. The efficacy data was deemed statistically significantly superior with a p<0.05.

"VOLT01 clearly demonstrated superior efficacy in controlling knee OA pain when compared to ZA alone," said Levolta Chief Medical Officer Ketan Desai, M.D., Ph.D. "In addition, the PDS associated with ZA administration was greatly reduced in VOLT01. It is important to note the sustained effect of VOLT01 treatment, with a significant reduction in pain still being reported at six months after a single infusion. We are hopeful that VOLT01 will be the first disease modifying osteoarthritis drug, with the potential to become a first line treatment for OA."

The United States Patent and Trademark Office (USPTO) recently awarded Levolta a patent for VOLT01, a derivative of ZA.

OA is a major, but poorly understood, public health problem. It is anticipated that OA will become the fourth leading cause of disability by 2020, according to the World Health Organization.

"There is currently no treatment that stops or delays OA progression," said Levolta Chief Executive Officer Richard P. Becker, Jr. "OA is a major burden on individuals, health care systems, and social service systems, which is expected to increase dramatically as our population ages. Successful VOLT01 Phase III trials will make it a first line defense against OA, providing payers with a pharmacoeconomic benefit through reduced joint replacement surgeries and significantly enhanced quality of life for patients."

A current Phase III multi-center clinical trial with Menzies Research Institute in Australia will assess VOLT01 for controlling knee osteoarthritis with results expected in 2015.

Levolta Pharmaceuticals, Inc.

Based in Bethlehem, Pa., Levolta Pharmaceuticals, Inc. , features a portfolio of early-stage small molecules and late-stage novel clinical compounds for rheumatology, the central nervous system, oncology and immunology. For more information, please call (848) 702-0682 or visit www.levoltapharma.com .

Fred Feiner Yankee Public Relations (908) 425-4878

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TORM Rejects Hafnia's No-Premium Merger Pitch Again

Updated Category News Views 112

A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 38

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 73

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 76

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 79

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 146

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
PARRIS Partners Earn 2026 Plaintiff Lawyer Recognition

Updated Category News Views 49

A $58.4 million jury number can make a courtroom sound like a slot machine, until the final settlement lands at $21 million. That gap is the part people ought to stare at before getting carried away by another plaintiff-lawyer honor roll. The Daily Journal has named PARRIS Law Firm partners Alexander R. Wheeler and Khail A. Parris to its 2026 Top Plaintiff Lawyers special...

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 165

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 171

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 138

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading

Top 5 Most Recently Viewed Articles

Artisan Partners Asset Management's Q2 Performance and Highlights

Updated Category News Views 124

Artisan Partners Asset Management Inc. Reports Strong Q2 Performance Artisan Partners Asset Management Inc. (NYSE: APAM) recently showcased its financial success for the quarter ending June 30, 2025. The Company, renowned for its investment strategies, declared a quarterly dividend as part of its results presentation. This reflects Artisan's commitment to providing value...

Continue Reading
LVMH Reports Recent Share Transactions and Market Activity

Updated Category News Views 240

Understanding LVMH's Share Transactions Recently, LVMH Moët Hennessy Louis Vuitton disclosed share transactions conducted between exciting dates. This information was provided to the regulatory body, ensuring transparency for investors and industry stakeholders alike. As one of the leading companies in the luxury goods sector, LVMH’s transactions are always...

Continue Reading
Dynavax Technologies to Share Insights at Healthcare Conference

Updated Category News Views 160

Dynavax's Upcoming Participation in Healthcare Conference Dynavax Technologies Corporation (Nasdaq: DVAX), a prominent player in the biopharmaceutical landscape, is set to take part in a pivotal fireside chat at the 8th Annual Evercore Healthcare Conference. This insightful event will take place on an upcoming Tuesday at 2:10 p.m. ET. Investors and healthcare stakeholders...

Continue Reading
Growing Demand for 3D Surveillance Cameras by 2030

Updated Category News Views 301

The Growing Market for 3D Surveillance Cameras The global 3D surveillance camera market is on the brink of substantial growth, with forecasts indicating it could reach an impressive $7.92 billion by 2030. This surge is primarily fueled by increased investments in defense and public safety initiatives around the world. A key factor in this trend is the rising use of 3D...

Continue Reading
LVMH Stock Upgrade by BofA Signals Strong Growth Ahead

Updated Category News Views 317

LVMH Receives Positive Rating Upgrade from Bank of America Recently, Bank of America made headlines by upgrading LVMH shares to a Buy rating, moving it from a previous Neutral stance. This upgrade places the renowned luxury goods giant on its prestigious Europe 1 list of preferred investment ideas. Revised Price Targets Indicate Strong Potential The ratings agency has...

Continue Reading